Faeth Therapeutics director owns 42,631 shares

Faeth Therapeutics, Inc. (FTH) reports that director Karen H. Vousden has filed an initial statement of beneficial ownership on Form 3.

Available on EDGAR 09/15/2026 - 04:57 PM EDT Accepted by SEC EDGAR 09/15/2026 - 04:57 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Faeth Therapeutics, Inc. (FTH) reports that director Karen H. Vousden has filed an initial statement of beneficial ownership on Form 3. The filing shows she holds 42,631 shares of the company's Common Stock with direct ownership, and it does not report any recent purchases or sales.

Insider Trade Summary

Holdings reported, no transactions

Holdings

Insider Vousden Karen H

Role Director

Type	Security	Shares	Price	Value
Holding	Common Stock	--	--	--

Holdings: Common Stock — 42,631 shares (Direct)

Key Figures

Common Stock held: 42,631 shares Holding entries reported: 1 entry Buy transactions reported: 0 transactions

3 metrics

Common Stock held 42,631 shares Total shares of Faeth Therapeutics, Inc. Common Stock owned following the reported position

Holding entries reported 1 entry Number of holding entries for Common Stock in the Form 3

Buy transactions reported 0 transactions Count of buy transactions in the transaction summary

Key Terms

Common Stock, Form 3, beneficial ownership

3 terms

Common Stock financial

"The filing reports ownership of Common Stock of Faeth Therapeutics, Inc."

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 3 regulatory

"Karen H. Vousden has filed an initial statement of beneficial ownership on Form 3."

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

beneficial ownership financial

"The Form 3 filing discloses that she beneficially owns 42,631 shares."

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 3 filing for FTH disclose about Karen H. Vousden?

The Form 3 filing discloses that director Karen H. Vousden beneficially owns 42,631 shares of Faeth Therapeutics, Inc. Common Stock, held with direct ownership. It is an initial ownership report and does not reflect a new transaction.

How many Faeth Therapeutics (FTH) shares does Karen H. Vousden own?

According to the Form 3, Karen H. Vousden owns 42,631 shares of Faeth Therapeutics, Inc. Common Stock following the reported position. These shares are reported as held directly.

Does the FTH Form 3 show any recent buy or sell transactions by Karen H. Vousden?

No. The Form 3 records a holding entry for Common Stock and shows 42,631 shares owned following the reported position, but it does not report any shares as bought or sold in a specific transaction.

Is Karen H. Vousden a director or officer of Faeth Therapeutics (FTH)?

The Form 3 identifies Karen H. Vousden as a director of Faeth Therapeutics, Inc. She is not reported as an officer or a ten percent owner in this filing.

What type of security is reported in Karen H. Vousden’s FTH Form 3 filing?

The filing reports ownership of Common Stock of Faeth Therapeutics, Inc. The total reported ownership following the position is 42,631 shares, held directly.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Vousden Karen H

(Last) (First) (Middle)

C/O FAETH THERAPEUTICS, INC.

701 TILLERY STREET #12 #1010

(Street)

AUSTIN TEXAS 78702

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
09/11/2026

3. Issuer Name and Ticker or Trading Symbol
Faeth Therapeutics, Inc. [ FTH ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	42,631	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Josiah Craver, Attorney-in-Fact	09/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)